Početna stranicaGNLX • NASDAQ
add
Genelux Corp
Preth. zaklj. cijena
2,58 $
Dnevni raspon
2,58 $ - 2,58 $
Godišnji raspon
1,60 $ - 13,97 $
Tržišna kapitalizacija
89,11 mil. USD
Prosječna količina
114,55 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
U vijestima
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Prihod | — | — |
Operativni troškovi | 6,94 mil. | 30,79 % |
Neto dohodak | −6,47 mil. | −20,99 % |
Neto profitabilnost | — | — |
Zarada po dionici | −0,19 | 5,00 % |
EBITDA | −6,88 mil. | −33,07 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 34,06 mil. | 14,02 % |
Ukupna imovina | 40,27 mil. | 18,19 % |
Ukupne obveze | 7,18 mil. | −28,52 % |
Ukupni kapital | 33,09 mil. | — |
Dionice u optjecaju | 34,10 mil. | — |
Cijena prema knjigovodstvenoj vrijednosti | 2,66 | — |
Povrat imovine | −40,61 % | — |
Povrat kapitala | −46,27 % | — |
Tok novca
Neto promjena novca
| (USD) | ruj 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −6,47 mil. | −20,99 % |
Gotovina od poslovanja | −5,75 mil. | −71,22 % |
Gotovina iz ulaganja | 3,99 mil. | 1.541,16 % |
Gotovina iz financiranja | 0,00 | −100,00 % |
Neto promjena novca | −1,76 mil. | −164,35 % |
Slobodan tok novca | −3,23 mil. | −117,71 % |
Više
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Osnovano
2001
Web-lokacija
Zaposlenici
25
